Chesapeake Utilities (CPK) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Welcome to Chesapeake Utilities Corporation's First Quarter twenty twenty five Earnings Conference Call. I would now like to turn the call over to Lucia Dempsey, Head of Investor Relations. Speaker1 Thank you, and good morning, everyone. Today's presentation can be accessed on our website under the Investors page and Events and Presentations subsection. After our prepared remarks, we will open up the call for questions. On Sl ...

Lesaka Technologies (LSAK) Q3 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Welcome to Lusarcatec's webcast for the third quarter of fiscal twenty twenty five. As a reminder, the webcast is being recorded and the presentation can be accessed through the webcast link provided. Management will address any questions you may have at the end of the presentation. Participants, please enter your questions into the questions section of this webcast. The webcast link as well as our press release and investor ...

Himax Technologies (HIMX) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Hello, ladies and gentlemen. Welcome to the Himax Technologies Incorporation First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. Now I would like to turn the conference over to Ms. Karen Tao, Head of IR and PR at H ...

The Real Brokerage (REAX) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the RealBrokerage first quarter two thousand twenty five earnings call. At this time, all participants have been placed on a listen only mode, and we will open the floor for your questions and comments after the presentation. I will now turn the call over to Alex Lumpkin. Ma'am, the floor is yours. Speaker1 Thanks, and good morning. Thank you for standing by, and welcome to Th ...

Clear Secure (YOU) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good morning, and welcome to Clear's Fiscal First Quarter twenty twenty five Conference Call. We have with us today Karen Seidman Becker, Co Founder, Chair and Chief Executive Officer Michael Barkin, President and Jen Hsu, Chief Financial Officer. As a reminder, before we begin, today's discussion contains forward looking statements about the company's future business and financial performance. These are based on management's current ...

Veru (VERU) Q2 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 After this morning's discussion, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference call over to Mr. Sam Fish, Veru Inc. Executive Director, Investor Relations and Corporate Communications. Please go ahead, sir. Speaker1 Statements made on this conference call may be forward looking statements. Forward looking statements may include, but are not necessarily l ...

Financial Data and Key Metrics Changes - As of March 31, 2025, the company reported cash, cash equivalents, and investments totaling $245.5 million, which is expected to fund operations into 2027 [20] - Research and development expenses increased to $23.4 million for Q1 2025, up from $11.7 million in Q1 2024, primarily due to costs associated with the MM120 program [21] - General and administrative expenses decreased to $8.8 million in Q1 2025 from $10.5 million in Q1 2024, attributed mainly to stock-based compensation [21] Business Line Data and Key Metrics Changes - The company is advancing its lead program MM120, targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD) with three pivotal Phase 3 trials actively enrolling [6][20] - The trials, Voyage and Panorama for GAD, and EMERGE for MDD, are designed to assess the efficacy and safety of MM120 ODT [15][19] Market Data and Key Metrics Changes - The company noted a significant unmet need for treatments addressing GAD and MDD, with over 50 million people affected in the U.S. alone [7] - There is a growing awareness and recognition of anxiety disorders, which is expected to benefit clinical research and commercial opportunities for GAD treatments [37] Company Strategy and Development Direction - The company aims to position MM120 ODT as a best-in-class treatment for GAD and MDD, with a clear regulatory strategy and breakthrough therapy designation [7][22] - The new Chief Commercial Officer, Matt Wiley, is expected to lead the commercial strategy during this critical growth phase, leveraging his extensive experience in CNS and psychiatry [9][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential of MM120 ODT to redefine treatment paradigms for GAD and MDD [10][22] - The company anticipates top-line data readouts from the trials in 2026, which will be crucial for future commercialization efforts [20][22] Other Important Information - The company amended its loan agreement to provide greater financial flexibility, allowing access to up to $120 million based on milestone achievements [20] - The company is committed to ensuring participant safety in clinical trials, employing rigorous screening and monitoring processes [50][51] Q&A Session Summary Question: Clarification on the MDG trial and therapeutic effective dose - Management confirmed that the MDD study will not use an intermediate dose, focusing on 100 micrograms versus placebo, and indicated that the same therapeutic dose is expected to be effective in MDD as seen in GAD [24][26] Question: Insights from GAD epidemiology and treatment patterns - Management noted that there is increasing awareness of GAD, which is beneficial for recruitment and clinical trials, and emphasized the importance of understanding treatment patterns [31][37] Question: Engagement with the FDA amid leadership changes - Management reported strong ongoing engagement with the FDA, with no direct impact from recent leadership changes [40][42] Question: Steps to limit enrolling professional patients - The company has implemented strict screening processes to ensure appropriate patient selection and adherence to trial protocols [46][48] Question: Plans for interim data releases in 2025 - Management indicated that there are no plans to release unblinded data this year, focusing instead on executing the studies and ensuring high-quality results [56][58] Question: Market dynamics and commercial planning activities - The company is confident in addressing unmet needs in GAD and MDD, with plans to refine market positioning and messaging in the second half of the year [62][65]

Papa John’s International (PZZA) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Thank you for standing by. Welcome to Papa John's First Quarter twenty twenty five Conference Call and Webcast. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer To ask a question during this session, you'll need to press 11 on your telephone. If your question has been answered and you'd like to remove yourself from the queue, simply press 11 ag ...

Financial Data and Key Metrics Changes - In Q1 2025, total net revenue decreased by 1% year over year to $98.7 million, within the guidance range of $98 million to $100 million [22] - Adjusted EBITDA increased by 3.5% year over year to $18.1 million, exceeding the guidance range of $17 million to $18 million [19][22] - Adjusted EBITDA margins expanded from 17.6% in Q1 2024 to 18.4% in Q1 2025 [19] Business Line Data and Key Metrics Changes - Digital revenue grew by 6% year over year, accounting for 57% of total net revenue in Q1 2025, the highest percentage achieved by the company [6][30] - Townsquare Ignite, the digital advertising segment, saw net revenue increase by 7.6% year over year, with a profit margin of 21.5% [20] - Townsquare Interactive, the subscription-based digital marketing solutions segment, returned to year-over-year profit growth with a 22% increase in segment profit [21] Market Data and Key Metrics Changes - Broadcast advertising net revenue, excluding political, declined by 8.3% year over year, while total broadcast revenue decreased by 9.1% [22] - The company continues to gain local and national broadcast market share, despite the overall decline in the broadcast market [17] Company Strategy and Development Direction - The company reaffirms its digital-first local media strategy, focusing on markets outside the top 50 in the U.S. as a competitive advantage [30][31] - The digital platform is viewed as the growth engine, with plans to invest heavily in digital solutions and technology [6][30] - The media partnership strategy is expected to generate $50 million in revenue over the next three to five years, with a profit margin of approximately 20% [11][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic uncertainties and continue delivering strong cash flow [5][30] - The company anticipates continued growth in digital advertising revenue, with year-over-year growth rates expected in the mid-single digits for Q2 2025 [11][20] - Management highlighted the importance of maintaining a strong competitive advantage through organic growth and strategic partnerships [49][60] Other Important Information - The company ended Q1 2025 with $6 million in cash, down from $33 million at year-end due to various payments, including interest and dividends [25] - The board approved a quarterly dividend of $0.20 per share, reflecting a yield of approximately 11.5% based on the current share price [27] Q&A Session Summary Question: Can you discuss the competitive landscape for Ignite and revenue from markets without radio stations? - Management emphasized the competitive advantage of operating outside the top 50 markets and highlighted the sophistication and scale of their digital advertising solutions [36][38] Question: What percentage of broadcast advertisers also buy digital solutions? - The majority of broadcast advertisers also utilize digital solutions, with over 85% engaging in both [42][46] Question: What are the company's thoughts on potential deregulation in the broadcast industry? - Management expressed excitement about deregulation opportunities, indicating that they could pursue both organic growth and acquisitions in markets outside the top 50 [48][52] Question: How widely penetrated do you expect the media partnership area to be in the future? - Management noted significant growth potential in partnering outside the top 50 markets, with hundreds of opportunities available [56][60] Question: How are interactive subscribers dealing with current economic uncertainties? - Management observed a temporary pause in spending due to uncertainty but noted a recovery in May and June, indicating improved confidence among clients [62][66]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $9.4 million, a decrease of 8% compared to $10.2 million in Q1 2024 [5][16] - Gross profit for Q1 2025 decreased to $5.7 million from $5.9 million in the prior year, with a gross profit margin of 60.1%, up from 58.1% [17][18] - Net loss attributable to shareholders was $4.2 million or $0.10 per share, compared to $7.6 million or $0.22 per share in the prior year [19] Business Line Data and Key Metrics Changes - Advanced Energy segment revenue increased by 6% to $7.9 million, driven by stronger sales of single-use handpieces in the U.S. [6][16] - OEM segment sales decreased by 44.7% to approximately $1.2 million, attributed to lower sales volume to existing customers [17] Market Data and Key Metrics Changes - Domestic revenue decreased by 3.4% year-over-year to $6.7 million, while international revenue decreased by 17.7% to $2.7 million [17] - The company noted a stabilization in demand for capital equipment in the U.S., with year-over-year increases for two consecutive quarters [6] Company Strategy and Development Direction - The company is focusing on the Renuvion offering as a key product for addressing loose and lax skin, particularly for patients experiencing rapid weight loss due to GLP-1 drugs [10][11] - AON body contouring platform is expected to differentiate the company in the market, with a planned launch in the second half of 2025 pending FDA clearance [14][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged persistent macroeconomic headwinds but expressed optimism about the growth potential from the GLP-1 market [7][9] - The company expects to return to more normalized cash burn for the remainder of 2025, projecting cash flow into 2027 [20] Other Important Information - The company implemented significant cost-cutting measures, resulting in a decrease in operating expenses to $8.7 million from $12.6 million in the prior year [19] - Renuvion won the 2025 New Beauty Award for Best Minimally Invasive Skin Tightener, highlighting its market recognition [12] Q&A Session Summary Question: Progress on AON platform and customer enrollment - Management indicated they are not commenting on the AON pipeline yet but noted excitement in the marketplace regarding upgrades to the APYX-one console [24][25] Question: Demand for APYX One console upgrades - Management confirmed they are seeing increased demand for the APYX One console as customers prepare for AON [26][27] Question: Tariff impacts and supply chain - Management stated they have manufacturing flexibility between the U.S. and Bulgaria to mitigate potential tariff impacts [30][31] Question: Margin impact from tariffs - Management expects gross margins to remain around 60% for the year, indicating minimal impact from current tariff considerations [34] Question: Investments to support AON launch - Management emphasized that while controlling expenses is important, investments to support the AON launch will not be compromised [35]